GoodRx (GDRX) Competitors $4.39 0.00 (0.00%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$4.44 +0.05 (+1.14%) As of 10/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GDRX vs. AMTM, STNE, WPP, FTDR, DLO, HRI, HNGE, WSC, CARG, and ATHMShould you be buying GoodRx stock or one of its competitors? The main competitors of GoodRx include Amentum (AMTM), StoneCo (STNE), WPP (WPP), Frontdoor (FTDR), DLocal (DLO), Herc (HRI), Hinge Health (HNGE), WillScot (WSC), CarGurus (CARG), and Autohome (ATHM). These companies are all part of the "business services" industry. GoodRx vs. Its Competitors Amentum StoneCo WPP Frontdoor DLocal Herc Hinge Health WillScot CarGurus Autohome Amentum (NYSE:AMTM) and GoodRx (NASDAQ:GDRX) are both business services companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Do institutionals and insiders believe in AMTM or GDRX? 39.9% of Amentum shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 18.7% of Amentum shares are owned by insiders. Comparatively, 4.5% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, AMTM or GDRX? GoodRx has lower revenue, but higher earnings than Amentum. GoodRx is trading at a lower price-to-earnings ratio than Amentum, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmentum$12.68B0.48-$82M$0.3964.59GoodRx$792.32M1.93$16.39M$0.1043.90 Do analysts rate AMTM or GDRX? Amentum currently has a consensus price target of $28.40, indicating a potential upside of 12.74%. GoodRx has a consensus price target of $5.80, indicating a potential upside of 32.12%. Given GoodRx's stronger consensus rating and higher probable upside, analysts clearly believe GoodRx is more favorable than Amentum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amentum 2 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.36GoodRx 0 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.42 Is AMTM or GDRX more profitable? GoodRx has a net margin of 4.33% compared to Amentum's net margin of 0.41%. Amentum's return on equity of 10.90% beat GoodRx's return on equity.Company Net Margins Return on Equity Return on Assets Amentum0.41% 10.90% 4.18% GoodRx 4.33%8.86%4.50% Does the media favor AMTM or GDRX? In the previous week, Amentum had 1 more articles in the media than GoodRx. MarketBeat recorded 12 mentions for Amentum and 11 mentions for GoodRx. Amentum's average media sentiment score of 0.86 beat GoodRx's score of 0.42 indicating that Amentum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amentum 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 1 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAmentum beats GoodRx on 8 of the 15 factors compared between the two stocks. Get GoodRx News Delivered to You Automatically Sign up to receive the latest news and ratings for GDRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDRX vs. The Competition Export to ExcelMetricGoodRxMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53B$8.17B$6.09B$10.54BDividend YieldN/A2.83%5.69%4.71%P/E Ratio43.9074.0085.3527.60Price / Sales1.9333.35539.78202.41Price / Cash13.8022.8037.9261.55Price / Book2.326.9713.016.76Net Income$16.39M$247.60M$3.30B$275.88M7 Day Performance-2.23%1.11%4.34%2.81%1 Month Performance6.30%0.75%9.49%9.24%1 Year Performance-37.55%13.32%84.83%35.42% GoodRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDRXGoodRx4.1935 of 5 stars$4.39flat$5.80+32.1%-37.4%$1.53B$792.32M43.90950Analyst ForecastAMTMAmentum3.74 of 5 stars$22.80+1.0%$28.40+24.5%N/A$5.49B$8.39B11.0153,000Analyst ForecastSTNEStoneCo3.8283 of 5 stars$19.46+4.0%$16.56-14.9%+63.0%$5.35B$2.46B-27.8016,793Analyst ForecastWPPWPP1.7161 of 5 stars$24.40+1.5%N/A-51.1%$5.19B$18.84B4.09108,044Trending NewsAnalyst UpgradeFTDRFrontdoor3.2963 of 5 stars$66.68-0.4%$59.75-10.4%+37.6%$4.88B$1.84B17.082,120Positive NewsAnalyst DowngradeDLODLocal3.1483 of 5 stars$14.60+0.3%$14.00-4.1%+52.4%$4.55B$745.97M24.661,095News CoverageAnalyst ForecastHRIHerc3.7827 of 5 stars$113.56-4.5%$144.60+27.3%-23.5%$3.95B$3.57B10.717,600Analyst ForecastHNGEHinge HealthN/A$49.72+2.6%$57.13+14.9%N/A$3.80BN/A0.001,514Analyst ForecastWSCWillScot4.604 of 5 stars$20.71+0.7%$32.43+56.6%-38.1%$3.74B$2.40B14.904,500Analyst ForecastCARGCarGurus4.5991 of 5 stars$37.45-0.1%$38.46+2.7%+15.1%$3.72B$894.38M23.011,282Positive NewsAnalyst UpgradeATHMAutohome3.3188 of 5 stars$28.98-0.2%$36.00+24.2%-12.8%$3.39B$964.42M14.894,415Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Amentum Competitors StoneCo Competitors WPP Competitors Frontdoor Competitors DLocal Competitors Herc Competitors Hinge Health Competitors WillScot Competitors CarGurus Competitors Autohome Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GDRX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
